|
"In addition to coenzyme Q10 supplementation, which has been recommended for treatment of statin myopathy and which some patients do respond to, these data provide a rationale for consideration of the use of carnitine in these patients," Wortmann said. "For patients who do not respond to coenzyme Q10, I would suggest the use of carnitine."
What I am trying to indicate is that meds alone often do not fit the bill. Where CoQ10 doesn't work carnitine may. This is what carnitine did for this group of subjects. A significant reduction in glycemia is nothing to sneeze at, not to mention the other markers, however there are those who preach on the internets that nutritional supplements are a waste of time and money. They are not, and people need to know that.
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Galvano F, Li Volti G, Malaguarnera M, Avitabile T, Antic T, Vacante M, Malaguarnera M.
University of Catania, Department of Biological Chemistry, Medical Chemistry and Molecular Biology, Viale A. Doria 6, 95125 Catania, Italy. Abstract
AIM: The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.
PATIENTS/METHODS: In this double-blind, randomized clinical trial, 75 patients were assigned to one of two treatment groups for 4 months. Group A received simvastatin monotherapy; group B received L-carnitine and simvastatin. The following variables were assessed at baseline, after washout and at 1, 2, 3 and 4 months of treatment: body mass index, fasting plasma glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, Apolipoprotein A1, Apo B, lipoprotein(a) and apoprotein(a).
RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05).
CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100.
|